Avistone Biotechnology Co., Ltd.

This study tests a new drug called ANS02 in people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). The trial has two phases: first, finding a safe dose, then checking if the drug shrinks tumors. About 294 participants will take ANS02 a…

This early-stage study tests a new drug called ANS014004 in 63 adults with advanced solid tumors that have spread. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. Participants must have certain genetic changes (MET, ROS1, or NTRK) a…

This study tests a new drug called andamertinib, alone or with chemotherapy, against standard chemotherapy in people with advanced non-squamous lung cancer that has unusual EGFR mutations. About 40 participants who have not had prior treatment will be enrolled. The goal is to see…

This early-phase study tests a new drug called ANS03 in adults with advanced solid tumors that have specific gene changes (ROS1 or NTRK). The main goals are to check safety and find the right dose. About 96 participants will receive the drug, and doctors will monitor side effects…